Loss narrowed 57% to NZ$0.158m on a fifth straight zero-revenue half

What changed

Iperion remained a pre-revenue entity in HY26, with continuing-operations revenue again reported at $0 — unchanged versus HY25 and FY25. The reported loss narrowed materially: PBT and NPAT both improved 56.6% to a loss of NZ$0.158m, from a loss of NZ$0.364m in HY25. Operating cash outflow tightened to NZ$0.183m from NZ$0.268m (a 31.7% reduction in burn). Despite the ongoing burn, cash on hand rose to NZ$0.242m from NZ$0.087m a year earlier, implying a financing inflow during the period that is not visible in the supplied excerpts. The balance sheet, however, contracted sharply year on year: total assets fell 56.3% to NZ$0.271m, total liabilities fell 55.0% to NZ$0.081m, and total equity fell 56.8% to NZ$0.190m. No dividend was declared, consistent with FY25.

What matters

• Zero-revenue status is the dominant fact. A 57% improvement in the loss is arithmetically meaningful but operationally small — the absolute saving is ~NZ$0.21m, achieved entirely through cost reduction rather than any revenue traction. The antimicrobial license referenced in the excerpts contains minimum royalty performance targets, but no royalty income has yet been booked.
• Equity erosion outpaces the reported loss. Total equity is down NZ$0.250m year on year, against a cumulative reported loss across H2 FY25 plus HY26 of ~NZ$0.238m. The balance sheet has shrunk to a NZ$0.271m asset base, leaving the company structurally close to shell scale.
• Cash position improved despite operating burn. Cash up NZ$0.155m while operations consumed NZ$0.183m points to an external funding event during the period; the supplied data does not detail the financing line, which matters for assessing runway.

Expectations

No formal targets, guidance, or forward-work disclosures have been provided. There is therefore no quantified benchmark to test the result against. The HY25 / FY25 shape shows that 82% of the FY25 NPAT loss landed in H1 FY25, with only NZ$0.080m of additional loss in H2 — so HY26's NZ$0.158m loss is already running roughly twice the H2 FY25 burn rate, even as it improves on the H1 FY25 comparable. With revenue still at zero, the result neither supports nor refutes any commercialisation milestone; it simply documents continued cost-base operation.

Quality of result

The improvement is entirely a cost-line outcome, not an earnings-quality story. With no revenue, there is no gross margin, no working capital cycle, and no segment mix to interrogate — the ~NZ$0.21m PBT improvement reflects lower operating costs versus HY25. PBT equals NPAT in both periods (no tax distortion), so the headline figure is clean as far as it goes. The cash improvement is more durable than the cash position alone suggests: operating burn moderated, and the cash balance lift appears to have been topped up by financing, not generated operationally. Working capital, capex, debt, and net debt are all undisclosed.

Unresolved

• What financing event lifted cash from NZ$0.087m to NZ$0.242m, and on what terms?
• At a current burn rate of ~NZ$0.18m per half, how many further halves of runway does the NZ$0.242m cash balance plus any post-period funding actually provide?
• What is the status of the antimicrobial licence's minimum royalty obligations — are they being met, deferred, or at risk of triggering remedies?
• Why has total equity fallen further than the cumulative reported losses would suggest in isolation?
• Is there any commercial pipeline or contracted revenue that would convert the zero-revenue line in coming periods?

This briefing cannot assess runway adequacy, the source and terms of the apparent financing inflow, or the commercial status of the antimicrobial licence, because none of these are quantified in the supplied material.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.